Hepatitis C virus infection and renal disease after renal transplantation

Area of Science:

• Nephrology
• Hepatology
• Transplantation Immunology

Background:

• Hepatitis C virus (HCV) is a primary cause of chronic liver disease post-renal transplantation (RT).
• HCV is linked to glomerular diseases in both native and transplanted kidneys, including membranoproliferative glomerulonephritis (MPGN) and membranous glomerulonephritis (MGN).
• The exact prevalence of HCV-induced glomerulonephritis after RT remains unclear.

Purpose of the Study:

• To review the association between HCV infection and glomerulonephritis in renal transplant recipients.
• To discuss the pathogenesis, diagnosis, and potential treatment strategies for HCV-related kidney disease post-transplantation.

Main Methods:

• Literature review of studies investigating HCV infection and kidney diseases in renal transplant patients.
• Analysis of diagnostic methods, including renal biopsy with light microscopy, immunofluorescence, and electron microscopy.
• Evaluation of treatment outcomes for antiviral therapies in this population.

Main Results:

• HCV infection is associated with MPGN, MGN, and transplant glomerulopathy after RT.
• Immune complex deposition containing HCV proteins is the likely pathogenesis, similar to native kidneys.
• Standard interferon is contraindicated due to rejection risk; pegylated interferon and ribavirin have limited efficacy, though ribavirin may reduce proteinuria.
• Interferon therapy in dialysis patients may suppress HCV RNA and prevent glomerulonephritis post-RT.

Conclusions:

• HCV poses significant risks for renal transplant recipients, including graft loss and de novo glomerulonephritis.
• Renal biopsy is crucial for diagnosing HCV-related kidney disease.
• Emerging data suggest interferon may be beneficial in preventing glomerulonephritis in HCV-positive dialysis patients awaiting RT.